Benefício consistente do controle- QI+ Entrega automática de insulina numa gama de características de adultos com diabetes tipo 2
EndocrinologiaSobre o estudo
- Desenho
- Ensaio clínico randomizado
- Nível de evidência
- 2 · Nova evidência
- Revista
- Diabetes technology & therapeutics
- Publicado em
- 23 jan 2026
- Citações
- 0
O resumo deste estudo é do publisher e não tem licença aberta: por isso mostramos aqui só os dados do estudo, e o texto fica na fonte original, nos links abaixo.
O estudo original
Consistent Benefit of Control-IQ+ Automated Insulin Delivery Across a Range of Characteristics of Adults with Type 2 Diabetes
Lakshmi G. Singh, John Lum, Lauren Kanapka, Jordan E. Pinsker, Roy W. Beck, for the 2IQP Study Group
Descritores MeSH
- Insulin Infusion Systems
- Diabetes Mellitus, Type 2
- Hypoglycemic Agents
- Insulin
- Blood Glucose
- Female
- Glycated Hemoglobin
- Humans
- Male
- Middle Aged
Veja também
Estudos relacionados
- Efficacy and Safety of Tubeless Hybrid Closed-Loop Systems in Type 1 Diabetes: A Meta-Analysis of Randomized Controlled Trials
- Automated Insulin Delivery in Adults With Type 1 Diabetes and Suboptimal HbA1c During Prior Use of Insulin Pump and Continuous Glucose Monitoring: A Randomized Controlled Trial
- Hybrid closed-loop insulin delivery improves glycaemic control compared with sensor-augmented pump therapy: A meta-analysis of 'free-living' randomised trials in type 1 diabetes
- Continuous glucose monitoring in noninsulin-treated type 2 diabetes: A critical review of reported trials with an updated systematic review and meta-analysis of randomised controlled trials
- Additive Benefits of Control-IQ+ AID to GLP-1 Receptor Agonist Use in Adults With Type 2 Diabetes
- Adults With Type 2 Diabetes Benefit From Automated Insulin Delivery Irrespective of C-Peptide Level